Heath Lukatch - 31 Jan 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Director
Signature
Heath Lukatch, by /s/ Andrew Guggenhime, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
31 Jan 2024
Net transactions value
-$277,500
Form type
4
Filing time
02 Feb 2024, 16:40:28 UTC
Previous filing
31 Jan 2024
Next filing
10 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $80,000 +5,000 +89% $16.00 10,625 31 Jan 2024 Direct
transaction PCVX Common Stock Sale $357,500 -5,000 -47% $71.50 5,625 31 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -5,000 -45% $0.000000 6,000 31 Jan 2024 Common Stock 5,000 $16.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023.
F2 Fully vested and exercisable.